Efficacy of thoracoscopic lobectomy versus segmentectomy for T1bN0M0 non-small cell lung cancer: A retrospective cohort study
- VernacularTitle:胸腔镜肺叶切除术与肺段切除术治疗T1bN0M0期非小细胞肺癌的回顾性队列研究
- Author:
Xiaofeng HUANG
1
,
2
;
Guiping YU
1
,
2
;
Yedong MI
1
,
2
;
Yibo SHAN
1
,
2
;
Zhonghua QIN
1
,
2
Author Information
1. Department of Cardiothoracic Surgery, Jiangyin People&rsquo
2. s Hospital, Jiangyin, 214400, Jiangsu, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
thoracoscope;
lobectomy;
segmentectomy;
prognosis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(10):1296-1302
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of thoracoscopic lobectomy versus segmentectomy in the treatment of T1bN0M0 non-small cell lung cancer (NSCLC). Methods Clinical data of 181 patients with T1bN0M0 NSCLC admitted to our hospital from 2012 to 2015 were retrospectively analyzed. They were divided into a lobectomy group and a segmentectomy group according to surgical methods. There were 117 patients in the lobectomy group (46 males and 71 females aged 61.32±8.94 years) and 64 patients in the segmentectomy group (20 males and 44 females aged 58.55±12.57 years). Perioperative indicators and prognosis were compared between the two groups. Results The segmentectomy group had longer operation time, less intraoperative blood loss, shorter postoperative hospital stay and more preservation of lung function compared with the lobectomy group (P<0.05). The lobectomy group had higher consolidation tumor ratio, bigger tumor diameter, and more lymph node sampling compared with the segmentectomy group (P<0.05). There was no statistical difference in 5-year overall survival or recurrence-free survival between the two groups (P<0.05). Conclusion For patients with T1bN0M0 NSCLC, thoracoscopic segmentectomy and lobectomy have similar prognosis, but segmentectomy has advantages with less injury and faster recovery over lobectomy.
